Stock Events

Stock Events

biote 

$1.5450
16
-$0.01-0.32% Friday 20:00
+$0.05+2.91%Friday 23:46After hours

Statistics

Day High
1.545
Day Low
1.54
52W High
3.58
52W Low
1.27
Volume
1,844
Avg. Volume
-
Mkt Cap
44.31M
P/E Ratio
5.47
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.23
-0.03
0.17
0.37
Expected EPS
-0.005
Actual EPS
N/A

Financials

14.07%Profit Margin
Profitable
2021
2022
2023
2024
2025
192.22MRevenue
27.05MNet Income

Analyst Ratings

2.50Average Price Target
The highest estimate is 4.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BTMD. It's not an investment recommendation.
Realty Income
2
O
VICI Properties
2
VICI
HP
2
HPQ
Crocs
2
CROX

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the hormone replacement therapy market, directly competing with Biote's bioidentical hormone replacement therapy offerings.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio in healthcare, including hormone therapy products that compete with Biote's solutions.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on innovative biotechnologies and medical solutions that overlap with Biote's hormone therapy treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for its biopharmaceutical products, competes in the same biotech and healthcare sectors as Biote.
Merck
MRK
Mkt Cap366B
Merck operates in various healthcare segments, including hormone-related therapies, making it a competitor to Biote.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb's diverse pharmaceutical products place it in direct competition with Biote, especially in the biotech-driven therapy space.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including hormone therapies that compete with Biote's offerings.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk's focus on hormone replacement therapies, particularly in the diabetes and obesity areas, positions it as a competitor to Biote.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in biopharmaceuticals that target various medical conditions, competing with Biote in the broader biotech healthcare market.

About

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Show more...
CEO
Robert C. Peterson
Employees
223
Country
United States
ISIN
US0906831039

Listings

XNAS
US
BTMD
BOATS
BOATS
BTMD.BOATS

0 Comments

Share your thoughts

FAQ

What is biote stock price today?▼
The current price of BTMD is $1.55 USD — it has decreased by -0.32% in the past 24 hours. Watch biote stock price performance more closely on the chart.
What is biote stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange biote stocks are traded under the ticker BTMD.
Is biote stock price growing?▼
BTMD stock has fallen by -1.59% compared to the previous week, the month change is a -31.64% fall, over the last year biote has showed a -55.35% decrease.
What is biote market cap?▼
Today biote has the market capitalization of 44.31M
When is the next biote earnings date?▼
biote is going to release the next earnings report on November 10, 2026.
What were biote earnings last quarter?▼
BTMD earnings for the last quarter are -0.23 USD per share, whereas the estimation was 0.03 USD resulting in a -962.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is biote revenue for the last year?▼
biote revenue for the last year amounts to 192.22M USD.
What is biote net income for the last year?▼
BTMD net income for the last year is 27.05M USD.
How many employees does biote have?▼
As of September 05, 2026, the company has 223 employees.
In which sector is biote located?▼
biote operates in the Health & Wellness sector.
When did biote complete a stock split?▼
The last stock split for biote was on June 01, 2007 with a ratio of 1:10.
Where is biote headquartered?▼
biote is headquartered in IRVING, United States.